Please login to the form below

Not currently logged in
Email:
Password:

faldaprevir

This page shows the latest faldaprevir news and features for those working in and with pharma, biotech and healthcare.

Novartis pulls EMA application for expanded Tasigna use

Novartis pulls EMA application for expanded Tasigna use

Novartis pulls EMA application for expanded Tasigna use. And Boehringer confirms it won't seek approval for faldaprevir as it exits hepatitis C. ... Boehringer drops faldaprevir. Meanwhile Boehringer confirmed it has withdrawn the application for its

Latest news

  • Boehringer pulls faldaprevir and exits hepatitis C market Boehringer pulls faldaprevir and exits hepatitis C market

    Boehringer pulls faldaprevir and exits hepatitis C market. Unable to challenge all-oral options from Gilead and others. ... Germany's Boehringer Ingelheim is bowing out of the race to develop oral hepatitis C virus (HCV) therapies and has discontinued

  • Boehringer's faldaprevir set for rapid review in Europe Boehringer's faldaprevir set for rapid review in Europe

    Boehringer's faldaprevir set for rapid review in Europe. More competition in emerging hepatitis C market. ... Meanwhile, faldaprevir is also in pivotal trials as part of an interferon-free regimen alongside non-nucleoside polymerase inhibitor BI 207127

  • J&J wins FDA panel backing for hepatitis C drug J&J wins FDA panel backing for hepatitis C drug

    Other drugs emerging in the protease inhibitor class include Boehringer Ingelheim's faldaprevir, Merck's vaniprevir, Bristol-Myers Squibb's asunaprevir and AbbVie's ABT 450, which also claim superior viral

  • Boehringer says faldaprevir does well in Asian hepatitis C patients Boehringer says faldaprevir does well in Asian hepatitis C patients

    Boehringer says faldaprevir does well in Asian hepatitis C patients. Trial success in patients from Korea, Japan and Taiwan. ... Boehringer recently started pivotal trials of an interferon-free combination regimen for hepatitis C virus based on

  • Boehringer moves interferon-free hep C regimen into phase III Boehringer moves interferon-free hep C regimen into phase III

    The combination of two of Boehringer's oral hepatitis C drugs - faldaprevir and BI 207127 - plus ribavirin achieved viral cure rate of up to 85 per cent after just 28 weeks' ... Faldaprevir is a once-daily protease inhibitor while BI 207127 is a

More from news
Approximately 5 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Influencing behaviour change: Looking beyond market research
These strategies will give you the insight you need to influence behaviour change by creating a meaningful pharma customer journey....
Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...
How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma...

Infographics